Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Otsuka's Abilify Adds Oral Solution Formulation

This article was originally published in The Pink Sheet Daily

Executive Summary

The atypical antipsychotic's new formulation will be available in February, the companies say. Abilify is the second drug in the class available as an oral solution, after J&J's Risperdal. Supplemental NDAs for additional Abilify formulations are pending at FDA, Bristol says.

You may also be interested in...



Abilify Adds Bipolar Maintenance Claim And Cerebrovascular Warning

Bristol-Myers Squibb/Otsuka's atypical antipsychotic becomes second drug in class, after Lilly's Zyprexa, with bipolar maintenance indication. Abilify also joins Zyprexa and J&J's Risperdal with warning on cerebrovascular adverse events in elderly dementia patients.

Bristol/Otsuka’s Abilify New Rx Share Exceeds 10%

Total scripts for the atypical antipsychotic were 700,000 in the fourth quarter, up more than 10% sequentially. Abilify has received additional sales support from Bristol despite the company’s reduction in the overall size of its detail team.

Bristol/Otsuka’s Abilify New Rx Share Exceeds 10%

Total scripts for the atypical antipsychotic were 700,000 in the fourth quarter, up more than 10% sequentially. Abilify has received additional sales support from Bristol despite the company’s reduction in the overall size of its detail team.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel